46% similarity to each other outside the divergent N Several different terms have been used to describe terminus. Nuclear localization of GRAS proteins may the mechanism by which proteins move intercellularly.
indicating that SCR-GFP did not move. Thus, subcellular variably expressed. Figure 2D shows a root expressing GFP-tagged SHR from the SCR promoter. In these roots, localization of SHR in stele cells is a property of sequence differences between SHR and SCR. The lack of SHR-GFP was observed only in the nuclei of the ground tissue. We were unable to detect it in the stele, sug-SHR in the cytoplasm of the endodermis (Figure 2A ) reveals a difference between these tissues in recognizgesting either that cytoplasmic SHR is required for movement or that SHR trafficking is unidirectional. Eiing these sequences.
ther indicates that SHR movement is regulated. The second approach taken was to reduce the amount Cytoplasmic Localization Is Required for SHR Movement of SHR in the cytoplasm. We fused a nuclear-localized version of GFP (nlsGFP) to SHR and drove it from the Given that the subcellular localization of SHR is intrinsic to the SHR protein and is regulated differently in endo-SHR promoter. This resulted in nearly complete nuclear localization ( Figure 2E ) and lack of movement. Unlike dermal and stele cells, we asked whether cytoplasmic localization of SHR is necessary for trafficking or, con-SHR-GFP, SHR-nlsGFP was not detected in the endodermis, the QC, the phloem precursor cells, or the periversely, whether completely nuclear-localized SHR can move. Because, in the endodermis, SHR is detected cycle cells adjacent to them. SHR-nlsGFP expressed from the SCR promoter was detectable, indicating that exclusively in the nucleus, movement of SHR-GFP from the endodermis into the pericycle would indicate that the NLS did not affect SHR stability in endodermal cells. Also, these roots were phenotypically identical to those cytoplasmic localization is not required for movement. Therefore, we expressed SHR-GFP in the endodermis expressing SHR-GFP from the SCR promoter (data not shown). Collectively, these data indicate that SHR moveby using the SCR promoter. As previously reported [8] , expression of untagged SHR from the SCR promoter ment requires cytoplasmic localization and suggest that restriction of SHR to endodermal nuclei may be a signifiresults in an increase in the number of ground tissue layers. In these additional layers the SCR promoter is cant mechanism regulating SHR movement. 
A Point Mutation that Disrupts SHR Movement
The dependence of SHR movement on cytoplasmic localization suggests two models for SHR trafficking. First, SHR movement is nontargeted (passive). Because it is in the cytoplasm, the protein can diffuse through plasmodesmata like GFP and LFY [4, 9], whose movement can be manipulated by modifying the degree of nuclear localization, with an increase correlating with less movement. Second, SHR movement is targeted, and the protein must be in the cytoplasm to interact with proteins that facilitate its movement. We have identified a new allele of shr, shr-5, that points to the second model. This allele has a missense mutation replacing threonine 289 with isoleucine (T289I). The shr-5 phenotype is as severe as that of shr-1, suggesting that shr-5 is a null allele. We introduced this mutation into the SHR-GFP protein (SHRTϾI-GFP) and drove it from the SHR promoter in both wild-type (Figures 3A and 3B ) and shr-2 plants (data not shown). In contrast to SHR-GFP, there was not distinct nuclear localization of SHRTϾI-GFP in the stele; fluorescence was distributed diffusely throughout the cytoplasm. Moreover, it was not detectable in any of the cells into which SHR normally trafficks ( Figure 3B ), suggesting that SHR does not move by passive diffusion.
Alternatively, the mutant protein may have trafficked into the endodermis and been efficiently degraded there. This might be expected if in wild-type roots a "fail-safe" mechanism exists that prevents movement out of endodermal cells by efficiently degrading any SHR protein not in the nucleus. To test this idea for the mutant protein, we expressed it directly in the endodermis and found that it accumulated to well above detectible levels ( Figure 3C ). This finding is inconsistent with a model in which rapid degradation of the mutant protein occurs in the cytoplasm of the endodermis, indicating instead that the lack of SHRTϾI-GFP reflects a lack of movement into endodermal cells.
Thus, although cytoplasmic localization of SHR is required for its movement, it is not sufficient. This is in contrast with the movement of LFY and GFP. Significantly, no mutation of LFY that is able to prevent its translocation has been found. In contrast, KN1, thiore- folding generally leads to degradation or aggregation [19, 20] . The robust fluorescence of SHRTϾI-GFP (Figures 3G and 3H ) as compared to that of wild-type SHR-GFP ( Figures 3E and 3F) argues against selective or to move and to function as a transcriptional regulator.
